Patient preferences for treatment of advanced melanoma

• Verfasst von: Weilandt, Juliane [VerfasserIn]
• Verfasst von: Diehl, Katharina [VerfasserIn]
• Verfasst von: Schaarschmidt, Marthe-Lisa [VerfasserIn]
• Verfasst von: Kiecker, Felix [VerfasserIn]
• Verfasst von: Sasama, Bianca [VerfasserIn]
• Verfasst von: Pronk, Melanie [VerfasserIn]
• Verfasst von: Ohletz, Jan [VerfasserIn]
• Verfasst von: Könnecke, Andreas [VerfasserIn]
• Verfasst von: Müller, Verena [VerfasserIn]
• Verfasst von: Utikal, Jochen [VerfasserIn]
• Verfasst von: Hillen, Uwe [VerfasserIn]
• Verfasst von: Harth, Wolfgang [VerfasserIn]
• Verfasst von: Ludwig-Peitsch, Wiebke [VerfasserIn]
• Titel: Patient preferences for treatment of advanced melanoma
• Titelzusatz: impact of comorbidities
• Verf.angabe: Juliane Weilandt, Katharina Diehl, Marthe-Lisa Schaarschmidt, Felix Kiecker, Bianca Sasama, Melanie Pronk, Jan Ohletz, Andreas Könnecke, Verena Müller, Jochen Utikal, Uwe Hillen, Wolfgang Harth, Wiebke K. Peitsch
• Jahr: 2021
• Umfang: 13 S.
• Fussnoten: First published: 04 October 2020 ; Gesehen am 13.04.2021
• Titel Quelle: Enthalten in: Deutsche Dermatologische GesellschaftJournal der Deutschen Dermatologischen Gesellschaft
• Ort Quelle: Berlin : Wiley-Blackwell, 2003
• Jahr Quelle: 2021
• Band/Heft Quelle: 19(2021), 1 vom: Jan., Seite 58-70
• ISSN Quelle: 1610-0387
• DOI: doi:10.1111/ddg.14293
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1753967805

Abstract

Background and objectives Choice of treatment for advanced melanoma is crucially influenced by comorbidities and patient preferences. Our study aimed to investigate the impact of comorbidities on preferences. Patients and methods 150 patients with melanoma stage IIC-IV completed a discrete choice experiment to determine preferences for outcome (overall response rate [ORR], 2-year survival, progression-free survival [PFS], time to response [TTR], kind of adverse events [AE], AE-related treatment discontinuation) and process attributes (frequency and route of administration [RoA], frequency of consultations) of systemic melanoma treatments. The impact of comorbidities was assessed by analysis of variance and multivariate regression. Results Participants with hypertension and other cardiovascular diseases attached significantly greater importance to TTR and RoA than others. Respondents with arthropathy cared more about TTR (β = 0.179, P = 0.047) and RoA, but less about ORR (β = -0.209, P = 0.021). Individuals with diabetes considered AE (β = 0.185, P = 0.039) and frequency of consultations more essential, but ORR less relevant. Those with other malignancies were particularly worried about treatment discontinuation (β = 0.219, P = 0.008), but less about ORR (β = -0.202, P = 0.015). Participants with depression focused more on PFS (β = 0.201, P = 0.025) and less on TTR (β = -0.201, P = 0.023) and RoA (β = -0.167, P = 0.050). Conclusions Treatment preferences of melanoma patients vary significantly dependent on comorbidities.